Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
StockNews.AI · 2 hours
AI Summary
Rhythm disclosed six-month Phase 2 results for setmelanotide in Prader-Willi syndrome, showing BMI reductions, favorable body composition, and meaningful improvements in hyperphagia and anxiety. With most patients still on therapy and Phase 3 planning underway, the data de-risk the program and could drive near-term investor interest ahead of ENDO 2026 presentations and the June 13 conference call.
Sentiment Rationale
Positive six-month Phase 2 data and clear Phase 3 intent reduce execution risk; potential uptick on ENDO data and June 13 call in near term, with longer runway if Phase 3 proves durable.
Trading Thesis
Bullish within 3–6 months on Phase 3 progression and data credibility.
Market-Moving
- Endo 2026 presentations and June 13 conference call could trigger intraday moves.
- Positive Phase 2 data may accelerate Phase 3 planning, expanding TAM considerations.
- PWS addressable patient base supports long-run upside beyond current indications.
Key Facts
- Phase 2 PWS data show BMI reductions, lean mass gains, and fat-mass loss.
- BMI fell 3.06% overall (N=17); adults -3.11% with several >2.5%, >4%.
- Lean mass +0.74% and fat mass -4.19% (DEXA, N=16) across groups.
- HQ-CT reductions ≥7 points in 8 of 10; PADQ improved in 10 of 15.
- 52-week Phase 2 ongoing; 17/18 enrolled active as of Jun 12; ENDO 2026 data.
Companies Mentioned
- Rhythm Pharmaceuticals, Inc. (RYTM): Phase 2 PWS data for setmelanotide; potential Phase 3 pathway and stock catalyst.
- ENDO 2026 conference (N/A): Data presentations and investor call may drive near-term volatility.
- University of Florida (N/A): PI-led study commentary lends credibility to results; no direct market impact.
Industry News
Industry News: Direct corporate development around Rhythm's Phase 2 results for setmelanotide in PWS; data-driven catalysts and upcoming events align with potential re-rating if Phase 3 timelines stay on track.